Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Clinical trial NCT06088290 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06088290
- Sponsor
- PharmaMar
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-21
- Primary completion
- 2029-08-30
- Enrollment
- 469
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.